Reinventing Women’s Incontinence Care

Amara Therapeutics are developing digital therapies that help women living with incontinence take control of their lives

Amara is elevating the standard of care for women living with incontinence by providing accessible evidence-based care. We combine cutting edge digital medicine with experienced human care to ensure every woman has access to world class incontinence care, regardless of their location, time constraints, or ability to pay.

Our Values

RESPECT

As it is difficult to seek help for incontinence, we aim to build relationships with our patients based on honesty, empathy and respect.

EMPOWERMENT

Our goal is to inspire confidence in body and mind. We enable women to understand and take control of their condition.

COMMUNITY

We strive to support patients and create a sense of belonging, so women don’t suffer alone and in-silence.

INTEGRITY

We work with experts and patients to provide innovative, evidence-based care pathways aligned with clinical guidelines.

78 million women suffer from incontinence in the US

Source: Patel UJ, Godecker AL, Giles DL, Brown HW. Updated Prevalence of Urinary Incontinence in Women: 2015-2018 National Population-Based Survey Data. Female Pelvic Med Reconstruction Surgery. 2022 Apr 1;28(4): 181-187. Dot: 10.1097/SPV.0000000000001127. Pub 2022 Jan 12. PMID: 35030139

Urinary incontinence is:

Common

A recent study revealed that the prevenance has grown to 60% of women, which equals 78 million women in the United States. ¹

Burdensome

One in five suffer from severe incontinence that limits daily activities such as exercise routines, and nearly 15% simply stay home. Given the deterioration in social and personal support, sleep, and self-esteem, it is not surprising that incontinence is strongly associated with depression and anxiety. ²

Costly

Urinary incontinence also undermines occupational performance, through increasing missed days, disability claims, and unemployment. Societal costs were estimated at more than $82 billion in 2020 with women bearing most of the burden.³

Poorly treated

The current care pathway for women who suffer from urinary incontinence is broken. Half of women don’t even pursue clinical care due to embarrassment and barriers to care. Most general practitioners are not trained to treat urinary incontinence while the specialists who are in short supply.⁴

Patel UJ, Godecker AL, Giles DL, Brown HW. Updated Prevalence of Urinary Incontinence in Women: 2015-2018 National Population-Based Survey Data. Female Pelvic Med Reconstr Surg. 2022 Apr 1;28(4):181-187. doi: 10.1097/SPV.0000000000001127. Epub 2022 Jan 12. PMID: 35030139
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327–36.
Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014 Feb;20(2):130-40. ‍
Vethanayagam N, Orrell A, Dahlberg L, McKee KJ, Orme S, Parker SG, Gilhooly M. Understanding help-seeking in older people with urinary incontinence: an interview study. Health Soc Care Community. 2017 May;25(3):1061-1069.

‍

Clinical Trial Evidence

Amara Therapeutics is building a foundation of evidence for effective behavioural therapies and virtual care

Pilot Study of a Digital Behavioral Therapy for OAB

RiSolve Clinical Trial

Our Products

RiSolve® is a CE marked Digital behavioural therapy for women with Overactive Bladder.

Simple and Convenient - Treatment direct to your smartphone at any time.

Non-Drug Therapy - Our digital intervention is a real alternative to medications.

Clinically Evaluated- Our multisite clinical trial shows improvements in OAB symptoms and improvement in quality of life.

View Website

View RiSolve IFU

Disclaimer: Caution: Investigational Device. Limited by United States law to investigational use. Commercially approved in limited jurisdictions. Contact info@risolvedtx.com for further information.

Meet The Team

Brendan Staunton

Chief Executive Officer

BSc, MSc, MBA

Brendan Staunton is the co-founder and CEO of Amara Therapeutics. Brendan has over a decade of medical device commercialisation experience working with several international medical device companies at senior management level.

Dr. Emma Carr

Chief Operating Officer

M.Ps.S.I, BA, H.Dip, MSc, PhD.

Emma Carr is the co-founder and Chief Operating Officer of Amara Therapeutics. Emma is a chartered health psychologist, experienced in developing and executing digital health interventions and clinical trials.

Dr. Geoffrey Cundiff

Chief Medical Officer

MD, FACOG, FACS, FRCSC

Dr. Geoffrey Cundiff is a co-founder and CMO of Amara Therapeutics. He is also a Professor in the Department of Obstetrics and Gynaecology at the University of British Columbia, where he is a research scientist at the Centre for Health…

Katie Dunne

Senior Quality Engineer

BA, MSc

Katie Dunne is our Senior Quality Engineer at Amara Therapeutics. Katie has over ten years of experience working within large multi-national medical device companies, primarily as a Quality Engineer supporting manufacturing, problem-solving and continuous…

Emily McLucas

RA/QA/CA

BSc, PhD

Emily McLucas PhD is a medical device professional with over 18 years’ experience bringing medical devices from concept through to global markets, including US and EU. Emily has held R&D, Quality, Regulatory and Clinical roles in start-up and multi-national companies developing devices from low to high risk (Class I to Class III).

Andrew Gallagher

Project Manager

Andrew Gallagher is a PM at Amara. He has a degree in mechanical engineering and previously founded a digital health company in the respiratory space.